The U.S. Food and Drug Administration declined to approve Aquestive Therapeutics Inc.’s erectile dysfunction treatment tadalafil and sought additional data.

First-Line Combination of Letairis and Tadalafil Reduced Risk of Disease Progression by Nearly 50 Percent Compared to Either Therapy Individually in Study of 605 PAH Patients with WHO Functional Class II-III Symptoms   October 02, 2015 06:19 PM Eastern Daylight Time   FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food […]